Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Oragenics (NYSE American: OGEN), a company developing intranasal pharmaceuticals for neurological disorders, has announced the pricing of a public offering of up to 800,000 shares of Series H Convertible Preferred Stock and Warrants. The combined offering price is set at $25.00 per unit, with the potential to raise up to $20 million in gross proceeds.
The Preferred Stock is convertible into common stock at $2.50 per share, and the Warrants allow purchase of additional Preferred Stock at $25.00 per share. The offering is expected to close around July 2, 2025. Dawson James Securities is serving as the sole placement agent.
The company plans to use the proceeds to fund its ONP-2 concussion clinical trials, related R&D activities, repay a $3 million bridge note, and for working capital and general corporate purposes.
Oragenics (NYSE American: OGEN), un'azienda che sviluppa farmaci intranasali per disturbi neurologici, ha annunciato il prezzo di un'offerta pubblica fino a 800.000 azioni di Serie H di Azioni Preferenziali Convertibili e Warrants. Il prezzo combinato dell'offerta 猫 fissato a 25,00 $ per unit脿, con la possibilit脿 di raccogliere fino a 20 milioni di dollari di proventi lordi.
Le Azioni Preferenziali sono convertibili in azioni ordinarie al prezzo di 2,50 $ per azione, mentre i Warrants consentono l'acquisto di ulteriori Azioni Preferenziali a 25,00 $ per azione. La chiusura dell'offerta 猫 prevista intorno al 2 luglio 2025. Dawson James Securities agisce come unico agente di collocamento.
L'azienda prevede di utilizzare i fondi per finanziare i suoi trial clinici ONP-2 sulla commozione cerebrale, le attivit脿 di ricerca e sviluppo correlate, rimborsare un prestito ponte da 3 milioni di dollari e per il capitale circolante e scopi aziendali generali.
Oragenics (NYSE American: OGEN), una empresa que desarrolla productos farmac茅uticos intranasales para trastornos neurol贸gicos, ha anunciado el precio de una oferta p煤blica de hasta 800,000 acciones de Acciones Preferentes Convertibles Serie H y Warrants. El precio combinado de la oferta se establece en $25.00 por unidad, con la posibilidad de recaudar hasta $20 millones en ingresos brutos.
Las Acciones Preferentes son convertibles en acciones comunes a $2.50 por acci贸n, y los Warrants permiten la compra de acciones preferentes adicionales a $25.00 por acci贸n. Se espera que la oferta cierre alrededor del 2 de julio de 2025. Dawson James Securities act煤a como agente colocador exclusivo.
La empresa planea usar los ingresos para financiar sus ensayos cl铆nicos ONP-2 para conmociones cerebrales, actividades relacionadas de I+D, pagar un pr茅stamo puente de $3 millones y para capital de trabajo y prop贸sitos corporativos generales.
Oragenics (NYSE American: OGEN)電� 鞁犼步 歆堩櫂 旃橂毳� 鞙勴暅 牍勱皶 雮� 鞎诫 臧滊皽 須岇偓搿滌劀, 鞁滊Μ歃� H 鞝勴櫂 鞖办劆欤� 氚� 鞗岆煱韸� 800,000欤�旯岇鞚� 瓿惦臧�毳� 氚滍憸頄堨姷雼堧嫟. 雼渼雼� 25.00雼煬鞚� 瓴绊暕 瓿惦臧�搿� 斓滊寑 2,000毵� 雼煬鞚� 齑� 靾橃澋鞚� 氇笀頃� 靾� 鞛堨姷雼堧嫟.
鞖办劆欤茧姅 欤茧嫻 2.50雼煬鞐� 氤错喌欤茧 鞝勴櫂 臧�電ロ晿氅�, 鞗岆煱韸鸽姅 欤茧嫻 25.00雼煬鞐� 於旉皜 鞖办劆欤茧ゼ 甑Г頃� 靾� 鞛堧姅 甓岆Μ毳� 鞝滉车頃╇媹雼�. 瓿惦電� 2025雲� 7鞗� 2鞚�瓴� 毵堦皭霅� 鞓堨爼鞛呺媹雼�. Dawson James Securities臧� 雼弲 氚办爼 旮瓣磤鞙茧 頇滊彊頃╇媹雼�.
須岇偓電� 靾橃澋旮堨潉 ONP-2 雵岇韮� 鞛勳儊鞁滍棙瓿� 甏�霠� 鞐瓣惮臧滊皽 頇滊彊, 300毵� 雼煬 敫岆Μ歆� 雲疙姼 靸來櫂, 攴鸽Μ瓿� 鞖挫爠 鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄頃� 瓿勴殟鞛呺媹雼�.
Oragenics (NYSE American : OGEN), une soci茅t茅 d茅veloppant des m茅dicaments intranasaux pour les troubles neurologiques, a annonc茅 le prix d'une offre publique portant sur jusqu'脿 800 000 actions privil茅gi茅es convertibles de s茅rie H et bons de souscription. Le prix unitaire combin茅 est fix茅 脿 25,00 $ par unit茅, avec une lev茅e potentielle de fonds bruts allant jusqu'脿 20 millions de dollars.
Les actions privil茅gi茅es sont convertibles en actions ordinaires 脿 2,50 $ par action, et les bons permettent l'achat d'actions privil茅gi茅es suppl茅mentaires 脿 25,00 $ par action. La cl么ture de l'offre est pr茅vue aux alentours du 2 juillet 2025. Dawson James Securities agit en tant qu'agent unique de placement.
La soci茅t茅 pr茅voit d'utiliser les fonds pour financer ses essais cliniques ONP-2 sur la commotion c茅r茅brale, les activit茅s de R&D associ茅es, rembourser un pr锚t relais de 3 millions de dollars et pour le fonds de roulement ainsi que des besoins g茅n茅raux d'entreprise.
Oragenics (NYSE American: OGEN), ein Unternehmen, das intranasale Medikamente f眉r neurologische Erkrankungen entwickelt, hat die Preisfestsetzung eines 枚ffentlichen Angebots von bis zu 800.000 Aktien der Serie H wandelbaren Vorzugsaktien und Warrants bekanntgegeben. Der kombinierte Angebotspreis liegt bei 25,00 $ pro Einheit und k枚nnte bis zu 20 Millionen $ Bruttoerl枚s einbringen.
Die Vorzugsaktien sind wandelbar in Stammaktien zu 2,50 $ pro Aktie, und die Warrants berechtigen zum Kauf zus盲tzlicher Vorzugsaktien zu 25,00 $ pro Aktie. Der Abschluss des Angebots wird um den 2. Juli 2025 erwartet. Dawson James Securities fungiert als alleiniger Platzierungsagent.
Das Unternehmen plant, die Erl枚se zur Finanzierung der ONP-2 Gehirnersch眉tterungs-Studien, damit verbundener F&E-Aktivit盲ten, zur R眉ckzahlung einer 3-惭颈濒濒颈辞苍别苍-顿辞濒濒补谤-叠谤眉肠办别苍苍辞迟别 sowie f眉r Betriebskapital und allgemeine Unternehmenszwecke zu verwenden.
- Potential to raise up to $20 million in gross proceeds to fund operations
- Funds will support ongoing ONP-2 concussion clinical trials and R&D activities
- Successfully secured Dawson James Securities as placement agent
- $3 million of proceeds will be used to repay existing bridge note debt
- Potential dilution for existing shareholders through preferred stock conversion
- Complex security structure with both preferred shares and warrants may impact trading dynamics
Insights
Oragenics raises up to $20M through preferred stock offering to fund concussion drug trials and repay debt, diluting existing shareholders.
Oragenics has announced a $20 million capital raise through convertible preferred stock and warrants, with each preferred share priced at
The company has clearly outlined its use of proceeds: funding clinical trials for ONP-2 (their concussion treatment candidate), repaying a
This financing comes at a critical juncture for Oragenics, which has pivoted to focus on intranasal pharmaceuticals for neurological disorders. The company's ability to secure this placement with Dawson James Securities suggests institutional support for their clinical development pathway, though the convertible nature of the offering indicates potential pressure on share price once conversion occurs.
The repayment of the
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced聽that it has entered into a placement agency agreement for the purchase聽and sale of up to 800,000 shares of the Company鈥檚 Series H Convertible Preferred Stock (鈥淧referred Stock鈥�), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of
The gross proceeds of the Offering are anticipated to be up to approximately
Dawson James Securities, Inc. is acting as the sole placement agent for the Offering.
The Offering is being made pursuant to a registration statement on Form S-1 (File No. 333-288225), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�) on June 23, 2025, and declared effective on June 30, 2025. The Offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the Offering has been or will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may also be obtained from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432, or by telephone at (561) 391-5555, or by email at [email protected]. Before investing in this Offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such Offering, which will provide more information about Oragenics and the Offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit聽www.oragenics.com.
Forward-Looking Statements
This communication contains 鈥渇orward-looking statements鈥� within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including 聽 those relating to the completion of the public Offering, the satisfaction of customary closing conditions, the intended use of proceeds from the public Offering and other statements that are predictive in nature. These forward-looking statements are based on management鈥檚 beliefs and assumptions and information currently available. The words 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渆stimate,鈥� 鈥減roject鈥� and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Oragenics, Inc.
Janet Huffman, Chief Executive Officer
813-286-7900
[email protected]
Investor Contact
Rich Cockrell
404.736.3838
FAQ
What is the size of Oragenics (OGEN) July 2025 public offering?
What is the conversion price for OGEN's Series H Preferred Stock?
How will Oragenics use the proceeds from its 2025 offering?
When will OGEN's 2025 preferred stock offering close?
What is the warrant exercise price in OGEN's 2025 offering?
